Skip to content

Debt-to-assets at other companies

Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×-0.3×
Janux Therapeutics logo
Janux TherapeuticsJANX
0.0×

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total equity$408.7M-30.8%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.14B+151%
Enterprise value$1.06B+181%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Calculated from Cullinan Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s debt-to-assets?
Cullinan Therapeutics, Inc. (CGEM) reported debt-to-assets of 0× in Q1 2026.
How has Cullinan Therapeutics, Inc.'s debt-to-assets changed year-over-year?
Cullinan Therapeutics, Inc.'s debt-to-assets increased by 84.4% year-over-year, from 0× to 0×.
What is the long-term trend for Cullinan Therapeutics, Inc.'s debt-to-assets?
Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s debt-to-assets has grown at a 17.9% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.